Medifast, Inc. (MED) is a publicly traded Consumer Cyclical sector company. As of May 21, 2026, MED trades at $12.62 with a market cap of $138.43M and a P/E ratio of -6.95. MED moved -0.28% today. Year to date, MED is +15.07%; over the trailing twelve months it is -9.61%. Its 52-week range spans $9.22 to $21.98. Analyst consensus is neutral with an average price target of $12.00. Rallies surfaces MED's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Medifast’s Optavia Cuts Visceral Fat by 14% While Preserving 98% Lean Mass: Medifast’s Optavia program delivered a 14% visceral fat reduction and preserved 98% lean mass over 16 weeks in randomized trials, supported by 18 RCTs and 40+ peer-reviewed publications. Structured meal replacements with coach support outperformed self-directed diets in fat mass loss and sustainable metabolic health outcomes.
| Metric | Value |
|---|---|
| Price | $12.62 |
| Market Cap | $138.43M |
| P/E Ratio | -6.95 |
| EPS | $-1.82 |
| Dividend Yield | 1.65% |
| 52-Week High | $21.98 |
| 52-Week Low | $9.22 |
| Volume | 10 |
| Avg Volume | 0 |
| Revenue (TTM) | $346.10M |
| Net Income | $-20.02M |
| Gross Margin | 70.12% |
1 analysts cover MED: 0 strong buy, 0 buy, 1 hold, 0 sell, 0 strong sell. Consensus rating is neutral. Average price target: $12.00.